Table 3

Table 3A
	S1PR2 Asn10Lys
	Asn10Asn	Asn10Lys	Lys10Lys	Pearson Chi²
hypertension	58.90% (1949)	57.02% (65)	100% (1)	0.6503
no hypertension	41.10% (1360)	42.98% (49)	0% (0)	0.6503
acute coronary syndrome	31.07% (1028)	31.58% (36)	100% (1)	0.3281
no acute coronary syndrome	68.93% (2281)	68.42% (78)	0% (0)	0.3281
left ventricular hypertrophy	8.25% (273)	5.26% (6)	0% (0)	0.4960
no left ventricular hypertrophy	91.75% (3036)	94.74% (108)	100% (1)	0.4960
coronary artery disease	77.33% (2559)	80.70% (92)	100% (1)	0.6045
no coronary artery disease	22.67% (750)	19.30% (22)	0% (0)	0.6045
peripheral vascular disease	9.73% (322)	8.77% (10)	0% (0)	0.8944
no peripheral vascular disease	90.27% (2987)	91.23% (104)	100% (1)	0.8944
angina pectoris	53.78% (1715)	53.15% (59)	0% (0)	0.5546
no angina pectoris	46.22% (1474)	46.85% (52)	100% (1)	0.5546
myocardial infarction	39.62% (1311)	47.37% (54)	100% (1)	0.1184
no myocardial infarction	60.38% (1998)	53.63% (60)	0% (0)	0.1184
unrecognized myocardial infarction	8.77% (237)	5.49% (5)	0% (0)	0.5253
no unrecognized myocardial infarction	91.23% (2466)	94.51% (86)	100% (1)	0.5253
premature myocardial infarction	17.53% (580)	18.42% (21)	100% (1)	0.8721
no premature myocardial infarction	82.47% (2729)	81.58% (93)	0% (0)	0.8721
venous thrombosis / pulmonary embolism	6.30% (208)	4.39% (5)	100% (1)	0.6846
no venous thrombosis / pulmonary embolism	93.70% (3093)	95.61% (109)	0% (0)	0.6846
stroke/TIA/PRIND	8.04% (266)	7.89% (9)	100% (1)	0.9558
no stroke/TIA/PRIND	91.96% (3043)	92.11% (105)	0% (0)	0.9558
arrhythmia	14.84% (485)	15.93% (18)	0% (0)	0.0546
no arrhythmia	85.16% (2783)	84.07% (95)	100% (1)	0.0546
diabetes	31.58% (1045)	35.96% (41)	0% (0)	0.2093
no diabetes	68.42% (2264)	64.04% (73)	100% (1)	0.2093

Table 3B
	S1PR2 Val286Ala
	Val286Val	Val286Ala	Pearson Chi²
hypertension	58.82% (1970)	61.97% (44)	0.5937
no hypertension	41.18% (1379)	38.03% (27)	0.5937
acute coronary syndrome	31.17% (1044)	30.99% (22)	0.9731
no acute coronary syndrome	68.83% (2305)	69.01% (49)	0.9731
left ventricular hypertrophy	8.09% (271)	11.27% (8)	0.3334
no left ventricular hypertrophy	91.91% (3078)	88.73% (63)	0.3334
coronary artery disease	77.61% (2599)	74.65% (53)	0.5546
no coronary artery disease	22.39% (759)	25.35% (18)	0.5546
peripheral vascular disease	9.73% (326)	9.86% (7)	0.9720
no peripheral vascular disease	90.27% (3023)	90.14% (64)	0.9720
angina pectoris	53.72% (1735)	59.70% (40)	0.3306
no angina pectoris	46.28% (1495)	40.30% (27)	0.3306
myocardial infarction	40.13% (1344)	30.99% (22)	0.1195
no myocardial infarction	59.87% (2005)	69.01% (49)	0.1195
unrecognized myocardial infarction	8.62% (236)	10.71% (6)	0.5818
no unrecognized myocardial infarction	91.38% (2501)	89.29% (50)	0.5818
premature myocardial infarction	17.62% (590)	11.27% (8)	0.1634
no premature myocardial infarction	82.38% (2759)	88.73% (63)	0.1634
venous thrombosis / pulmonary embolism	6.14% (205)	11.27% (8)	0.0770
no venous thrombosis / pulmonary embolism	93.86% (3136)	88.73% (63)	0.0770
stroke/TIA/PRIND	8.06% (270)	5.63% (4)	0.4558
no stroke/TIA/PRIND	91.94% (3079)	94.37% (67)	0.4558
arrhythmia	15.03% (497)	11.43% (8)	0.4033
no arrhythmia	84.97% (2810)	88.57% (62)	0.4033
diabetes	31.50% (1055)	49.30% (35)	0.0015 *0.0008
no diabetes	68.50% (2294)	50.70% (36)	0.0015 *0.0008
* After logistic regression for age, body mass index, gender and smoker status. Risk ratio for incidence of diabetes 1.084 (95% CI 1.035-1.140).

Table 3: Association analyses between the S1PR2 polymorphisms Asn10Lys (Table 3A) and Val286Ala (Table 3B) and clinical endpoints in patients of the LURIC study. Figures indicate the percentage (%) and number of patients with the given clinical endpoint in the group of individuals with the same S1PR2 genotype. The clinical endpoints listed in the tables are based on questionnaire data, the patient record or have been diagnosed during hospitalization/inclusion phase in the LURIC study. Definitions for disease diagnosis are listed in Patients and Methods under Study Population.